Chargement de la fiche…
Chargement de la fiche…
rhumatologie
Praticien hospitalier
Paris 13e Arrondissement (75651)
Rheumatoid Arthritis Research and Therapies · Spondyloarthritis Studies and Treatments · Psoriasis: Treatment and Pathogenesis
Tout est calculé à partir des sources publiques (RPPS, PubMed, OpenAlex, OpenStreetMap…) — aucun classement éditorial.
2024
Griffith University
2022
University of North Carolina at Chapel Hill
2018–2019
Délégation Paris 5
2017
Goethe University Frankfurt
2017
Uppsala University
2004–2014
Délégation Paris 5
0
h-index
0
i10
0
citations
Le h-index mesure la productivité scientifique : ce médecin a publié 94 articles cités au moins 94fois par d'autres chercheurs. Plus c'est élevé, plus son travail influence la communauté médicale.
Côté patient
Comprendre votre pathologie, exercices à domicile, applications validées, paramédicaux à proximité — gratuit, sans inscription.
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'Études Spécialisées
DE Docteur en médecine — Capacité / Certificat d'Études Spéciales
0
travaux
0
h-index
0
i10-index
0
citations
2026Clinical rheumatology
PubMed ↗Do the Psoriatic Arthritis Impact of Disease's cutoffs vary across ethnicities? Insights from the TACTIC initiative
2026Annals of the rheumatic diseases
PubMed ↗Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study
2026Rheumatology advances in practice
PubMed ↗Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies
2026Annals of the rheumatic diseases
PubMed ↗The positive perspective paradigm: proposal of a model to mitigate the impact of chronic inflammatory arthritis through comprehensive and early intervention
2026The Journal of rheumatology
PubMed ↗Further Validation of a Questionnaire to Assess Flare in Psoriatic Arthritis: Determination of Cutoff and Longitudinal Change
2026Annals of the rheumatic diseases
PubMed ↗EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
2026Annals of the rheumatic diseases
PubMed ↗Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment
2026Rheumatology (Oxford, England)
PubMed ↗Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas
2026RMD open
PubMed ↗Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort
2025The Journal of rheumatology
PubMed ↗Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic Arthritis
2025Scandinavian journal of rheumatology
PubMed ↗Global health in axial spondyloarthritis: thresholds for the Assessment of SpondyloArthritis international Society Health Index and the EuroQol score: analysis of the ASAS-PerSpA study
2025La Revue du praticien
PubMed ↗[Treatment of psoriatic arthritis]
2025Joint bone spine
PubMed ↗Factors associated with dietary practices and beliefs on food of patients with rheumatic and musculoskeletal diseases: A multicentre cross-sectional study
2025Joint bone spine
PubMed ↗Early peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort
2025Rheumatology (Oxford, England)
PubMed ↗Subclinical psoriatic arthritis and disease interception-where are we in 2024?
2025Osteoarthritis and cartilage open
PubMed ↗Greater pain and functional impairment in chronic erosive hand osteoarthritis compared to treated rheumatoid arthritis: A comparative study
2025Rheumatology (Oxford, England)
PubMed ↗Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study
2025Rheumatology international
PubMed ↗Discordance between patient and physician global assessments of psoriatic arthritis activity: an observational study in 13 Arab countries
2025BMC rheumatology
PubMed ↗Disease activity during pregnancy in patients with rheumatoid arthritis or spondyloarthritis: results from the multicentre prospective GR2 study
2024RMD open
PubMed ↗Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data
2024Joint bone spine
PubMed ↗Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop
2024Rheumatology (Oxford, England)
PubMed ↗An international multicentre analysis of current prescribing practices and shared decision-making in psoriatic arthritis
2024RMD open
PubMed ↗Different disease activity trajectories in early axial spondyloarthritis lead to significantly different long-term outcomes: a trajectory-based analysis of the DESIR cohort over 10 years
2026Annals of the rheumatic diseases
PubMed ↗Final validation of the hierarchical framework for outcomes in axial spondyloarthritis: longitudinal determinants of health-related quality of life
2026ACR open rheumatology
PubMed ↗Control of Inflammation and Sustained Improvements in Patient-Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two-Year Results From Two Phase 3 Studies
2025Rheumatology (Oxford, England)
PubMed ↗How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients
2025Rheumatology international
PubMed ↗Impact of concomitant fibromyalgia on patient-reported outcomes and inflammatory markers in psoriatic arthritis: a multinational cross-sectional study
2025Arthritis research & therapy
PubMed ↗Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study
2025The Journal of rheumatology
PubMed ↗Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies
2026Annals of the rheumatic diseases
PubMed ↗Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414
2025The Journal of rheumatology
PubMed ↗Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
2025Annals of the rheumatic diseases
PubMed ↗Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial
2025Annals of the rheumatic diseases
PubMed ↗Remote monitoring or patient-initiated care in axial spondyloarthritis: a 3-armed randomised controlled noninferiority trial
2025The Journal of rheumatology
PubMed ↗Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies
2026Annals of the rheumatic diseases
PubMed ↗Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414
2026Rheumatology (Oxford, England)
PubMed ↗Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies
2025ACR open rheumatology
PubMed ↗Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study
2025Rheumatology and therapy
PubMed ↗Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
2025Rheumatology and therapy
PubMed ↗Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
2026Rheumatology and therapy
PubMed ↗Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study
2025Arthritis research & therapy
PubMed ↗Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials
2025RMD open
PubMed ↗Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
2025Rheumatology (Oxford, England)
PubMed ↗Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS
2026Rheumatology and therapy
PubMed ↗Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study
2024BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
PubMed ↗Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
2025Rheumatology and therapy
PubMed ↗Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial
2025Rheumatology and therapy
PubMed ↗Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials
2026Annals of the rheumatic diseases
PubMed ↗EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis
2025Annals of the rheumatic diseases
PubMed ↗Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
2025The Journal of rheumatology
PubMed ↗Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
2024Arthritis care & research
PubMed ↗Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review
2025Arthritis research & therapy
PubMed ↗Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials
2025Rheumatology (Oxford, England)
PubMed ↗Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS
2025JMIR human factors
PubMed ↗Feasibility of Long-Term Physical Activity Measurement With a Wearable Activity Tracker in Patients With Axial Spondyloarthritis: 1-Year Longitudinal Observational Study
2024RMD open
PubMed ↗NSAID exposure delays time-to-pregnancy in patients with spondyloarthritis: an analysis of the GR2 prospective cohort
2025Annals of the rheumatic diseases
PubMed ↗Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial
2025ACR open rheumatology
PubMed ↗Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study
2025Arthritis research & therapy
PubMed ↗Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials
2024Arthritis care & research
PubMed ↗Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review
2024Arthritis care & research
PubMed ↗Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review
2025The Journal of rheumatology
PubMed ↗Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
2026Article
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectives
Expert Opinion on Biological Therapy
2026Article
Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort
RMD Open
2026Article
Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study
Annals of the Rheumatic Diseases
2026Article
Guselkumab Improves Patient-Reported Outcomes Among Participants With Psoriatic Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors in the COSMOS Study
Rheumatology and Therapy
2026Article
Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study
Rheumatology and Therapy
2026Article
Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis Atlas
Rheumatology
2025Article
Impact of Concomitant Fibromyalgia on Patient-Reported Outcomes and Inflammatory Markers in Psoriatic Arthritis: A Multinational Cross-Sectional Study
Rheumatology International
2025Article
Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified With Machine Learning Analytics Using Data From Biologic DMARD-Naïve Patients in Two Phase 3 Clinical Trials
Arthritis Research & Therapy